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SPAIN Study: Dual-Chamber Pacing With Closed 
Loop Stimulation (DDD-CLS) Reduced Syncope 
Burden and Time to First Recurrence by 7-Fold, 
and Prolonged Time to First Syncope Recurrence in 
Patients Age≥40 Years With Tilt-Induced Cardio-
inhibitory Vasovagal Syncope  
DDD-CLS pacing is a rate-responsive mode that 
uses intracardiac impedance as a surrogate of cardiac 
contractility to adapt heart rate to patient needs. Among 
46 patients, aged 56.30 ± 10.63 years, with tilt-induced 
cardioinhibitory vasovagal syncope, the proportion of 
patients with ≥50% reduction in the number of 
syncopal episodes was 72% with DDD-CLS compared 
with 28% with sham DDI mode (p=0.017). A total of 4 
patients (8.7%) had events during DDD-CLS and 21 
(45.7%) during sham DDI (hazard ratio: 6.7). Kaplan-
Meier curve was significantly different between groups 
in time to first syncope: 29.2 months vs 9.3 months (p< 
0.016); odds ratio: 0.11 (p< 0.0001) (Baron-Esquivias 
G et al, J Am Coll Cardiol 2017;70: 1720–28).   
PESA Study: Skipping Breakfast is Associated With an 
Increased Odds of Prevalent Noncoronary and 
Generalized Atherosclerosis Independently of the 
Presence of Conventional CV Risk Factors   
Three patterns of breakfast consumption were studied: 
high-energy breakfast, when contributing to >20% of total 
daily energy intake (27% of the population); low-energy 
breakfast, when contributing between 5% and 20% of total 
daily energy intake (70% of the population); and skipping 
breakfast, when consuming <5% of total daily energy (3% 
of the population). Independent of the presence of 
traditional and dietary cardiovascular (CV) risk factors, 
and compared with high-energy breakfast, habitual 
skipping breakfast was associated with a higher prevalence 
of noncoronary (odds ratio-OR: 1.55) and generalized 
(OR: 2.57) atherosclerosis (Uzhova I et al, J Am Coll 
Cardiol 2017;70: 1833-42).  
"Real life" Longevity of Implantable Cardioverter-
Defibrillator Devices (ICDs) Turns out Much Shorter 
than Manufacturers’ Projected Longevity 
Manufacturers of implantable cardioverter-
defibrillators (ICDs) promise a 5- to 9-year projected 
longevity; however, real-life data indicate otherwise. Over 
20 years, among 685 ICD patients (601 men; age, 
63.1 ± 13.3 years) with coronary (n = 396) or valvular 
(n = 15) disease, cardiomyopathy (n = 220), or electrical 
disease (n = 54) (mean ejection fraction 35%) and devices 
implanted for secondary (n = 562) or primary (n = 123) 
prevention (292 single-, 269 dual-chamber and 124 CRT 
devices implanted in the abdomen in 17 or chest in 668), 
ICD pulse generator replacements were performed in 238 
patients. These were 209 men and 29 women, aged 
63.7 ± 13.9 years, with ejection fraction of 37.7% ± 14.0%, 
who had an ICD for secondary (n = 210) or primary 
(n = 28) prevention. The mean ICD longevity was 
58.3 ± 18.7 months. In 20 (8.4%) patients, devices 
exhibited premature battery depletion within 36 months. 
Most (94%) patients had none, minor, or modest use of 
ICD therapy. Longevity was longest for single-chamber 
devices and shortest for CRT devices. Latest-generation 
devices replaced over the second decade lasted longer 
compared with devices replaced during the first decade. 
When analyzed by manufacturer, Medtronic devices 
appeared to have longer longevity by 13 to 18 months. The 
authors concluded that ICDs continue to have limited 
longevity of 4.9 ± 1.6 years, and 8% demonstrate 
premature battery depletion by 3 years. CRT devices have 
the shortest longevity (mean, 3.8 years) by 13 to 17 
months, compared with other ICD devices (Manolis AS et 
al, Clin Cardiol 2017;40:759-764).  
CAMERA-MRI Study: AF is an Underappreciated 
Reversible Cause of Left Ventricular Systolic 
Dysfunction (LVSD) Despite Adequate Rate Control / 
Restoration of Sinus Rhythm With Catheter Ablation 
(CA) Results in Significant Improvements in 
Ventricular Function, Particularly in the Absence of 
Ventricular Fibrosis on Cardiac MRI (CMR)  
Among patients (N=68) with persistent AF and 
idiopathic cardiomyopathy (LVEF ≤45%; average AF 
burden post-CA 1.6 ± 5.0% at 6 months), randomized to 
CA or medical therapy, absolute LVEF improved by 18 ± 
13% in the CA group compared with 4.4 ± 13% in the 
medical group (p< 0.0001) and normalized (LVEF≥50%) 
in 58% vs 9% (p=0.0002). In those undergoing CA, the 
absence of late gadolinium enhancement predicted greater 
improvements in absolute LVEF (10.7%; p=0.0069) and 
normalization at 6 months (73% vs 29%; p=0.0093) 
(Prabhu S et al, J Am Coll Cardiol 2017;70:1949–61).   
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Brugada Syndrome (BrS): ICD Therapy is an Effective 
Therapy in High-Risk Patients With BrS, Albeit with a 
Significant Risk of Device-Related Complications  
Among 104 patients with BrS having ICDs, for 
secondary prevention in 10 (9.6%) and primary prevention 
in 94 (90.4%), over 9.3 ± 5.1 years, 21 patients (20.2%) 
experienced 81 appropriate shocks. The rate of appropriate 
shocks was higher in secondary prevention patients 
(p<0.01). However, 4 of the 45 asymptomatic patients 
(8.9%) experienced appropriate ICD therapy, all with a 
spontaneous type 1 ECG and inducible ventricular 
arrhythmias. In multivariable analysis, type 1 ECG with 
syncope (hazard ratio -HR: 4.96; p< 0.01) and secondary 
prevention indication (HR: 6.85; p< 0.01) were significant 
predictors of appropriate therapy. A total of 37 inappro-
priate shocks occurred in 9 (8.7%), other ICD-related 
complications in 21 (20.2%), and deaths in 3 patients 
(2.9%) (1 electrical storm and 2 non-cardiovascular 
deaths) (Hernandez-Ojeda J et al, J Am Coll Cardiol 
2017;70:1991-2002).   
A High Percentage (49%) of 110 PFO/ASD Patients 
Were Also Migraine Sufferers / Percutaneous Closure 
Offered Migraine Relief in 83% of Patients, 82% in 
PFO Patients and 89% in ASD Patients 
In 110 patients, the impact of PFO (n=75) /ASD 
(n=35) closure on migraine was investigated. Closure was 
effected with an Amplatzer occluder in a simplified 
procedure, performed under local anesthesia with use of 
fluoroscopy alone without intra-procedural echocardiogra-
phic guidance. Complete sealing was obtained in 98.7% of 
PFO and 94.3% of ASD patients. All patients received dual 
antiplatelet therapy for 6 months. Among 54 (49%) 
patients suffering from migraine before the procedures (45 
PFO and 9 ASD patients), improvement (50%) or abolition 
(33.3%) of migraine occurred in 45 patients, 37 (82.2%) 
PFO and 8 (88.9%) ASD patients, yielding an overall 
favorable effect of 83.3%. An atrial septal aneurysm was 
present in 44 (58.7%) PFO patients, which has been 
considered an important predictor of migraine occurrence 
in PFO patients. Importantly, the favorable effect extended 
beyond the 6-month period when dual antiplatelet therapy 
was discontinued. Based on this experience and on 
literature review, a strategic approach for device closure is 
proposed for migraineurs with a PFO or ASD (Manolis 
AS, Rev Recent Clin Trials 2017;12:129-138).   
BIOSTAT-CHF / PCSK9-LDL Receptor (LDLR) Axis: 
Heart Failure (HF) Risk was Positively Associated with 
Circulating PCSK9 and Negatively Associated with 
LDLR in Patients with Worsening HF   
In 2,174 HF patients (aged 68±12 years; 53.2% with 
history of ischemic heart disease), during follow-up, 
multivariable analysis revealed a positive linear associa-
tion between PCSK9 levels and risk of mortality (hazard 
ratio -HR: 1.24; p=0.020) and the composite endpoint 
(mortality or hospitalization for HF) (HR: 1.21; p=0.010). 
A similar analysis for LDLR revealed a negative associa-
tion with mortality (HR: 0.86; p=0.025) and the composite 
endpoint (HR: 0.92; p=0.087). Including PCSK9 and 
LDLR improved risk score performance (Bayes-Genis A 
et al, J Am Coll Cardiol 2017;70:2128-36).  
PARADIGM-HF and ATMOSPHERE: Among Heart 
Failure (HF) Patients With a History of AF, Those 
With Paroxysmal AF (PAF) were at Greater Risk of 
HF Hospitalization and Stroke than Patients with 
Persistent or Permanent AF, Underlining the 
Importance of Anticoagulant Therapy / New Onset AF 
was Associated With Increased Risk of All Outcomes  
Among 15,415 HF patients (35.6% with history of AF, 
30% of these with PAF), patients with PAF had a higher 
risk of the primary composite endpoint of CV death or HF 
hospitalization (HR: 1.20; p< 0.001), HF hospitalization 
(HR: 1.34; p< 0.001), and stroke (HR: 1.34; p=0.037), 
whereas the respective risks in patients with persistent or 
permanent AF were not elevated. Neither type of AF was 
associated with higher mortality. New onset AF was 
associated with the greatest risk of adverse outcomes: 
primary endpoint (HR: 2.21), HF hospitalization (HR: 
2.11), stroke (HR: 2.20), and all-cause mortality (HR: 
2.26), all p < 0.001, compared with patients without AF. 
Anticoagulants were used less often in patients with PAF 
(53%) and new-onset (16%) AF than in patients with 
persistent or permanent AF (71%). (Mogensen UM et al, J 
Am Coll Cardiol 2017;70: 2490-2500).   
Among Patients Hospitalized With Heart Failure (HF), 
Ejection Fraction (EF) did not Influence a Poor 5-Year 
Survival and Elevated Risk for Cardiovascular and HF 
Admission 
Among 39,982 patients admitted for HF, 18,299 (46%) 
had HF with preserved EF ≥50% (HFpEF), 3,285 (8.2%) 
had HF with borderline EF 41%-49% (HFbEF), and 
18,398 (46%) had HF with reduced EF ≤40% (HFrEF). 
Overall, median survival was 2.1 years. In risk-adjusted 
survival analysis, all 3 groups had similar 5-year mortality 
(HFrEF 75.3% vs HFpEF 75.7%; hazard ratio-HR: 0.99; 
HFbEF 75.7% vs HFpEF 75.7%; HR: 0.99). The 
composite of mortality and rehospitalization was similar 
for all subgroups. Cardiovascular and HF readmission 
rates were higher in those with HFrEF and HFbEF 
compared with those with HFpEF (Shah KS et al, J Am 
Coll Cardiol 2017;70:2476-86).   
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COMPASS Trial: Patients with Stable Atherosclerotic 
Disease, Assigned to Rivaroxaban (2.5 mg bid) Plus 
Aspirin, Had Better CV Outcomes but More Major 
Bleeding Events Than Those Assigned to Aspirin Alone  
Among 27,395 participants randomized to rivaroxaban 
(2.5 mg bid) plus aspirin (100 mg qd), rivaroxaban (5 mg 
bid), or aspirin (100 mg qd), the primary outcome (CV 
death, stroke, or MI) occurred in fewer patients in the 
rivaroxaban-plus-aspirin group than in the aspirin-alone 
group (379 patients -4.1% vs 496 patients -5.4%; hazard 
ratio-HR, 0.76; P<0.001), but major bleeding events 
occurred in more patients in the rivaroxaban-plus-aspirin 
group (288 patients -3.1% vs 170 patients -1.9%; HR, 1.70; 
P<0.001). There was no difference in intracranial or fatal 
bleeding. There were 313 deaths (3.4%) in the rivaro-
xaban-plus-aspirin group vs 378 (4.1%) in the aspirin-
alone group (HR, 0.82; P=0.01). The primary outcome did 
not differ between patients in the rivaroxaban-alone group 
and the aspirin-alone group, but major bleeding events 
occurred in more patients in the rivaroxaban-alone group 
(Eikelboom JW et al, N Eng J Med 2017;377:1319-30 ).   
RE-DUAL PCI: Among Patients With AF Having Had 
PCI, the Risk of Bleeding was Lower Among Those 
Who Received Dual Therapy With Dabigatran and a 
P2Y12 Inhibitor Than Among Those Who Received 
Triple Therapy With Warfarin, a P2Y12 Inhibitor, and 
Aspirin / Dual was Noninferior to Triple Therapy 
Regarding Thromboembolic Events 
Among 2725 AF patients who had PCI, randomized to 
triple therapy (warfarin plus clopidogrel or ticagrelor) and 
aspirin (for 1-3 months) (triple-therapy group) or dual 
therapy with dabigatran (110 mg or 150 mg bid) plus a 
P2Y12 inhibitor (clopidogrel or ticagrelor) and no aspirin 
(110-mg and 150-mg dual-therapy groups), the incidence 
of the primary end point was 15.4% in the 110-mg dual-
therapy group vs 26.9% in the triple-therapy group (hazard 
ratio-HR, 0.52; P<0.001 for noninferiority & superiority) 
and 20.2% in the 150-mg dual-therapy group vs 25.7% in 
the triple-therapy group, which did not include elderly 
patients outside the United States (HR, 0.72; P<0.001 for 
noninferiority). The incidence of the composite efficacy 
end point was 13.7% in the two dual-therapy groups 
combined vs 13.4% in the triple-therapy group (HR, 1.04; 
P=0.005 for noninferiority). The rate of serious adverse 
events did not differ significantly among the groups. 
(Cannon CP et al, N Engl J Med 2017;377:1513-24).  
PREMIUM: PFO Closure did not Meet the Primary 
Endpoint of 50% Reduction in Migraine Attacks and 
Adverse Events in Patients With Frequent Migraine  
Among 230 PFO patients with migraine, there was no 
difference in responder rate in the PFO closure (45 of 117) 
vs control (33 of 103) groups. One serious adverse event 
(transient AF) occurred in 205 subjects who underwent 
PFO closure. Subjects in the PFO closure group had a 
significantly greater reduction in headache days (–3.4 vs –
2.0 days/month, p=0.025). Complete migraine remission 
for 1 year occurred in 10 patients (8.5%) in the treatment 
group vs 1 (1%) in the control group (p=0.01) (Tobis JM 
et al, J Am Coll Cardiol 2017;70:2766-74).   
The Long-Term Mortality Benefit Associated With a 
Mechanical vs a Biologic Prosthesis, Persisted Until 
Age 70 Among Patients Undergoing Mitral-Valve 
Replacement (MVR) and Until Age 55 Among Those 
Undergoing Aortic-Valve Replacement (AVR) 
From 1996 through 2013, the use of biologic 
prostheses increased substantially for AVR and MVR, 
from 11.5% to 51.6% for AVR and from 16.8% to 53.7% 
for MVR. Among patients who underwent AVR, receipt of 
a biologic prosthesis was associated with higher 15-year 
mortality than receipt of a mechanical prosthesis among 
patients 45 to 54 years of age (30.6% vs. 26.4% at 15 years; 
hazard ratio-HR, 1.23; P=0.03) but not among patients 55 
to 64 years of age. Among patients who underwent MVR, 
receipt of a biologic prosthesis was associated with higher 
mortality than receipt of a mechanical prosthesis among 
patients 40 to 49 years of age (44.1% vs 27.1%; HR, 1.88; 
P<0.001) and among those 50 to 69 years of age (50% vs. 
45.3%; HR, 1.16; P=0.01). The incidence of reoperation 
was significantly higher among recipients of a biologic 
prosthesis than among recipients of a mechanical 
prosthesis. Patients who received mechanical valves had a 
higher cumulative incidence of bleeding and, in some age 
groups, stroke than did recipients of a biologic prosthesis. 
(Goldstone AB et al, N Engl J Med 2017;377:1847-57).  
 
Compared With the Early-Generation Devices, TAVI 
Using the New-Generation Devices was Associated with 
Improved Procedural Outcomes in Patients With Pure 
Native Aortic Regurgitation (AR) / In Patients With 
Pure Native AR, Significant Post-Procedural AR was 
Independently Associated With Increased Mortality  
A total of 331 patients with AR and mean STS score of 
6.7 ± 6.7 underwent TAVI. The new-generation devices 
(n=212) were associated with a significantly higher device 
success rate (81.1% vs 61.3%; p< 0.001) due to lower rates 
of second valve implantation (12.7% vs 24.4%; p=0.007) 
and post-procedural AR ≥moderate (4.2% vs 18.8%; p< 
0.001). There were no significant differences in major 30-
day endpoints between the 2 groups. The cumulative rates 
of all-cause and cardiovascular death at 1-year follow-up 
were 24.1% and 15.6%, respectively. On multivariable 
analysis, post-procedural AR≥ moderate was 
independently associated with 1-year all-cause mortality 
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(hazard ratio: 2.85; p=0.001) (Yoon SH et al, J Am Coll 
Cardiol 2017; 70:2752-63).  
 
ASSERT II: Subclinical Atrial Fibrillation (SCAF) 
Frequently Detected by Continuous ECG Monitoring 
in Older Patients Without a History of AF Attending 
Outpatient Cardiology and Neurology Clinics 
Among 256 patients (aged >65; mean CHA2DS2-
VASc score was 4.1±1.4; left atrium 4.7±0.8 cm; 48% with 
prior stroke, TIA, or systemic embolism) with an 
implanted s.c. ECG monitor, followed up for 16.3±3.8 
months, SCAF ≥5 min was detected in 90 patients 
(detection rate, 34.4%/y). Baseline predictors of SCAF 
were increased age (hazard ratio -HR per decade, 1.55), 
left atrial dimension (HR per centimeter diameter, 1.43), 
and blood pressure (HR per 10 mm Hg, 0.87), but not prior 
stroke. The rate of occurrence of SCAF in those with a 
history of stroke, systemic embolism, or TIA was 39.4%/y 
vs 30.3%/y without (P=0.32). The cumulative SCAF 
detection rate was higher (51.9%/y) in those with left atrial 
volume above the median value of 73.5 mL (Healey JS et 
al, Circulation 2017;136:1276-83).    
Cardiac Implantable Electronic Device (CIED) Lead 
Extraction Can be Successful with Mechanical Tools 
Using the Lead-Locking Device (LLD) Stylet Aided by 
Non-Powered Telescoping Sheaths Through a Simple, 
Safe, & Inexpensive Procedure Using Local Anesthesia  
Among 54 patients (38 men and 16 women aged 
68.9±13.1 years), 98 leads were percutaneously extracted 
(78 pacing (31 ventricular, 37 atrial, 4 VDD, 6 coronary 
sinus leads) and 20 defibrillating leads) for device 
infection (n=46) (more commonly due to Staphylococcus 
species, n=40), lead malfunction (n=5), or prior to 
defibrillator implant (n=3). Leads were in place for 6.7±4.3 
years. Using simple traction (6 leads) and the LLD stylets 
(92 leads) aided with telescoping sheaths (15 patients), 96 
(98%) leads in 52 (96.3%) patients were successfully 
removed, with all but one lead removed using a subclavian 
approach; in 1 patient, the right femoral approach was also 
required. In 2 patients, distal fragments from one 
ventricular pacing and one defibrillating lead could not be 
removed. Finally, lead removal was completely (52/54) 
(96.3%) or partially (2/54) (3.7%) successful in 54 patients 
for 96 of 98 leads (98%) without major complications 
(Manolis AS et al, Anatol J Cardiol 2017;18:289-295).   
Lead Extraction for Noninfectious Indications Had 
Similar Long-Term Survival to That with Capping and 
Abandoning Leads / However, Extraction was Associated 
With Lower Risk of Device Infections at 5 Years  
Among 6859 patients, 1113 (16.2%) undergoing 
extraction and 5746 (83.8%) capping and abandonment, the 
overall 1-year and 5-year mortality was 13.5% and 54.3%, 
respectively. Extraction was associated with a lower risk of 
device infection at 5 years relative to capping (adjusted 
hazard ratio, 0.78; P=0.027). There was no association 
between extraction and mortality, lead revision, or lead 
extraction at 5 years (Pokorney SD et al, Circulation 
2017;136:1387-1395).  
ELECTRa Study: Confirmed the Safety and Efficacy 
of Current Practice of Transvenous Lead Extraction 
(TLE)/Higher Success Rate With Lower Complications 
and Mortality in High vs Low Volume Centers  
Among 3510 patients undergoing TLE, the primary 
endpoint of in-hospital procedure-related major 
complication rate was 1.7% (58/3510 pts) including a 
mortality of 0.5% (17/3510 pts). About two-thirds (37/58) 
of these complications occurred during the procedure and 
one-third (21/58) in the post-operative period. The most 
common procedure related complications were those 
requiring pericardiocentesis or chest tube and/or surgical 
repair (1.4%). Complete clinical and radiological success 
rates were 96.7% and 95.7%, respectively. The all cause 
in-hospital major complications and deaths were 
significantly lower in high (>30 procedures/y) volume 
(HiV) centers vs low (<30/y) volume (LoV) centers (2.4% 
vs 4.1%, P = 0.0146; and 1.2% vs 2.5%, P = 0.0088), 
although those related to the procedure did not reach 
statistical significance. Radiological and clinical successes 
were more frequent in HiV vs LoV centers (Bongiorni MG 
et al; Eur Heart J 2017;38:2995-3005).  
 
EARLY-MYO Trial: For Patients With STEMI 
Presenting ≤6h After Symptom Onset and With an 
Expected PCI-Related Delay, a Pharmacoinvasive 
(PhI) Strategy With Half-Dose Alteplase and Timely 
(3-24h) PCI Offers More Complete Reperfusion When 
Compared With Primary PCI (PPCI)  
Among 344 patients randomized to PhI strategy (half-
dose alteplase of 8-mg bolus followed by 42 mg in 90 min) 
(n=171) or PPCI (n=173), PhI was noninferior (and even 
superior) to PPCI for the primary end point (complete 
reperfusion) (34.2% vs 22.8%, Pnoninferiority<0.05, Psuperiority= 
0.022), with no significant differences in the frequency of: 
TIMI flow 3 (91.3% vs 89.2%, P=0.580), myocardial 
perfusion grade 3 (65.8% vs 62.9%, P=0.730), and ST-
segment resolution ≥70% (50.9% vs 45.5%, P=0.377). 
Infarct size (23.3%±11.3% vs 25.8%±13.7%, P=0.101) 
and LVEF (52.2%±11.0% vs 51.4%±12.0%, P=0.562) 
were similar. No significant differences occurred in 30-day 
rates of total death (0.6% vs 1.2%, P=1.0), reinfarction 
(0.6% vs 0.6%, P=1.0), heart failure (13.5% vs 16.2%, 
P=0.545), major bleeding (0.6% vs 0%, P=0.497), or 
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intracranial hemorrhage (0% vs 0%), but minor bleeding 
(26.9% vs 11.0%, P<0.001) was observed more often in 
the PhI group (Pu J et al, Circulation 2017;136:1462-
1473).   
Cardiac Myosin-Binding Protein C (cMyC) at 
Presentation Provides Discriminatory Power 
Comparable to hs-cTn in the Diagnosis of Acute Myo-
cardial Infarction (AMI) and May Perform Favorably 
in Patients Presenting Early After Symptom Onset  
cMyC, a cardiac-restricted protein, more abundant than 
cardiac troponins (cTn), released more rapidly after acute 
myocardial infarction (AMI), was measured in 1954 
patients presenting to the emergency department with 
symptoms suggestive of AMI (finally diagnosed in 340 
patients or 17%). Concentrations of cMyC at presentation 
were significantly higher in those with vs without AMI 
(median, 237 ng/L vs 13 ng/L, P<0.001). Discriminatory 
power for AMI was comparable for cMyC, hs-cTnT, and 
hs-cTnI and superior to cTnI measured by a contemporary 
sensitivity assay. Use of cMyC more accurately classified 
patients with a single blood test into rule-out or rule-in 
categories. In early presenters (chest pain <3 h), the 
improvement in rule-in/rule-out classification with cMyC 
was larger compared with hs-cTnT and hs-cTnI (P<0.001). 
Comparing the C statistics, cMyC was superior to hs-cTnI 
and standard sensitivity cTnI (P<0.05 for both) and similar 
to hs-cTnT at predicting death at 3 years (Kaier TE et al, 
Circulation 2017;136:1495-1508).   
Bilateral Internal Mammary Artery (BIMA) Grafting 
was Associated With a Reduced Risk of Repeat 
Revascularization and an Improvement in Long-Term 
Survival and Should be Considered More Frequently 
During Coronary Artery Bypass Grafting (CABG)  
Amon 47,984 consecutive CABGs, over a median of 
13.2 years, there was a higher freedom from repeat 
revascularization among patients receiving BIMA than 
those receiving single IMA (hazard ratio -HR, 0.78; 
P=0.009). Among the matched cohort, 19.4% (n=252) of 
patients receiving single IMA underwent repeat revascula-
rization (majority PCI), whereas this frequency was 15.1% 
(n=196) among patients receiving BIMA (P=0.004). 
BIMA grafting was associated with a reduction in all-cause 
mortality at 12 years of follow-up (HR, 0.79; P=0.001), 
and there was no difference in in-hospital morbidity 
(Iribarne A et al, Circulation 2017;136:1676-85).   
In Euthyroid Individuals, Higher Circulating Free T4 
(fT4) Levels, but not TSH Levels, are Associated With 
Increased Risk of Incident AF  
Of 30 085 participants from 11 cohorts, 1958 (6.5%) 
had subclinical hypothyroidism and 2574 individuals 
(8.6%) developed AF during follow-up. TSH at baseline 
was not significantly associated with incident AF in 
euthyroid participants or those with subclinical hypo-
thyroidism. Higher fT4 levels at baseline in euthyroid 
individuals were associated with increased AF risk in age- 
and sex-adjusted analyses (hazard ratio, 1.45, for the 
highest quartile vs the lowest quartile of fT4; P for trend 
≤0.001 across quartiles) (Baumgartner C et al, Circulation 
2017;136:2100-16).   
TROPICAL-ACS: Guided De-Escalation of Antiplatelet 
Treatment was Non-Inferior to Standard Treatment 
With Prasugrel at 1 Year After PCI   
Among 2610 ACS patients undergoing PCI, assigned 
to the guided de-escalation group (stage-adapted treatment 
with potent platelet inhibition in the acute phase and de-
escalation to clopidogrel in the maintenance phase: 1 week 
prasugrel followed by 1 week clopidogrel and platelet 
function testing-guided maintenance therapy with 
clopidogrel or prasugrel from day 14 after hospital 
discharge) (N=1304), or to the control group (prasugrel for 
12 months) (N=1306). The primary endpoint occurred in 
95 patients (7%) in the guided de-escalation group and in 
118 patients (9%) in the control group (pnon-inferiority=0.0004; 
hazard ratio -HR 0.81, psuperiority=0.12). Despite early de-
escalation, there was no increase in the combined risk of 
CV death, MI, or stroke in the de-escalation group (32 
patients [3%]) vs in the control group (42 patients - 3%; 
pnon-inferiority=0.0115). There were 64 bleeding events (5%) 
in the de-escalation group vs 79 events (6%) in the control 
group (HR 0.82; p=0.23) (Sibbin S et al, Lancet 2017;390: 
1747-57). 
 
PURE: Higher Fruit, Vegetable, and Legume 
Consumption (3-4 Servings or 375-500 g/d) was 
Associated With a Lower Risk of Non-Cardiovascular, 
and Total Mortality  
 
Among 135 335 individuals aged 35-70 years without 
cardiovascular (CV) disease, over a median 7.4 years, 
higher total fruit, vegetable, and legume intake was 
inversely associated with major CV disease, MI, CV 
mortality, non-CV mortality, and total mortality by 
univariate analysis. The estimates were substantially 
attenuated in the multivariable adjusted models for major 
CV disease (hazard ratio - HR 0.90, ptrend=0.1301), MI (HR 
0.99; ptrend=0.2033), stroke (HR 0.92; ptrend=0.7092), CV 
mortality (HR 0.73; ptrend=0.0568), non-CV mortality (HR 
0.84; ptrend=0ꞏ0038), and total mortality (HR 0.81; 
ptrend<0ꞏ0001). The HR for total mortality was lowest for 
3-4 servings per day (HR 0.78) compared with the 
reference group, with no further apparent decrease in HR 
with higher consumption. When examined separately, fruit 
21 
 
 
intake was associated with lower risk of CV, non-CV, and 
total mortality, while legume intake was inversely 
associated with non-CV death and total mortality. For 
vegetables, raw vegetable intake was strongly associated 
with a lower risk of total mortality, whereas cooked 
vegetable intake showed a modest benefit against mortality 
(Miller V et al, Lancet 2017;390:2037-49).  
 
PURE: High Carbohydrate Intake was Associated 
With Higher Risk of Total Mortality, While Total Fat 
and Individual Types of Fat Were Related to Lower 
Total Mortality / Total Fat and Types of Fat Were not 
Associated With Cardiovascular Disease (CVD), MI, or 
CVD Mortality, Whereas Saturated Fat Had an 
Inverse Association With Stroke  
Analysis of the dietary intake of 135 335 individuals 
indicated that higher carbohydrate intake was associated 
with an increased risk of total mortality (highest 5 vs 
lowest 1 quintile, HR 1.28, ptrend=0ꞏ0001) but not with the 
risk of CVD or CVD mortality. Intake of total fat and each 
type of fat was associated with lower risk of total mortality 
(quintile 5 vs quintile 1, total fat: HR 0.77, ptrend<0.0001; 
saturated fat, HR 0.86, ptrend=0ꞏ0088; monounsaturated fat: 
HR 0.81, ptrend<0ꞏ0001; and polyunsaturated fat: HR 0.80, 
ptrend<0ꞏ0001). Higher saturated fat intake was associated 
with lower risk of stroke (quintile 5 vs quintile 1, HR 0ꞏ79, 
ptrend=0.0498). Total fat and saturated and unsaturated fats 
were not significantly associated with risk of MI or CVD 
mortality (Dehghan M, et al, Lancet 2017;390:2050-62).  
PURE: Higher Physical Activity Conferred a Lower 
Risk of Mortality and Cardiovascular Disease (CVD) 
Events in Individuals from Low-, Middle-, and High-
Income Countries / Increasing Physical Activity is a 
Simple, Widely Applicable, Low Cost Global Strategy 
That Could Reduce Deaths and CVD in Middle Age  
Among 130,843 participants without pre-existing 
CVD, compared with low physical activity (<600 MET 
 × min/week or <150 min/w of moderate intensity physical 
activity), moderate (600–3000 MET × min or 150–750 
min/w) and high physical activity (>3000 MET × min or 
>750 min/w) were associated with graded reduction in 
mortality (hazard ratio - HR 0ꞏ80, and 0ꞏ65; p<0ꞏ0001 for 
trend), and major CVD (HR 0.86; p<0ꞏ001 for trend). 
Higher physical activity was associated with lower risk of 
CVD and mortality in high-, middle-, and low-income 
countries. The adjusted population attributable fraction for 
not meeting the physical activity guidelines was 8% for 
mortality and 4.6% for major CVD, and for not meeting 
high physical activity was 13% for mortality and 9.5% for 
major CVD. Both recreational and non-recreational 
physical activity were associated with benefits (Lear SA et 
al, Lancet 2017;390:2643-54).  
SPYRAL HTN-OFF MED: Results Provide Biological 
Proof of Principle for the Blood-Pressure-Lowering 
Efficacy of Renal Denervation 
Results of prior randomized renal denervation studies 
were inconsistent. A new study evaluated the effect of 
renal denervation on blood pressure (BP) in the absence of 
antihypertensive medications in 80 patients with an office 
systolic BP (SBP) of >150 mmHg and <180 mmHg, 
diastolic BP (DBP) of >90 mmHg, and a mean 24-h 
ambulatory SBP of >140 mmHg and <170 mmHg, 
randomly assigned to renal denervation (n=38) or sham 
control (n=42) and followed up for 3 months. Office and 
24-h ambulatory BP decreased significantly from baseline 
to 3 months in the renal denervation group: 24-h SBP −5.5 
mmHg (p=0.0031), 24-h DBP −4.8 mm Hg (p<0.0001), 
office SBP −10 mmHg (p=0.0004), and office DBP −5.3 
mmHg (p=0.0002). No significant changes were seen in 
the sham-control group. The mean difference between the 
groups favoured renal denervation for 3-month change in 
both office and 24-h BP from baseline. Baseline-adjusted 
analyses showed similar findings. There were no major 
adverse events in either group (Townsend RR et al, Lancet 
2017;390:2160-70).   
Everolimus-Eluting Bioresorbable Scaffolds (BVSs) vs 
Everolimus-Eluting Metallic Stents (EESs): BVSs 
Increased the Risks for Scaffold Thrombosis and Other 
Thrombotic Events at Mid- and Long-Term Follow-
Up, and Risks Increased Over Time  
Meta-analysis of 7 randomized and 38 observational 
studies indicated an incidence of definite or probable 
scaffold thrombosis after BVS implantation of 1.8% at a 
median of 1 year (41 studies, 21,884 patients) and 0.8% 
beyond 1 year (14 studies, 4688 patients). Seven trials 
involving 5578 patients that directly compared BVSs with 
EESs showed an increased risk for scaffold thrombosis 
(odds ratio - OR, 3.40) with BVSs at a median follow-up 
of 25 months. Increased risks were present at early 
(prominently subacute), late, and very late stages, and odds 
beyond 1 year were almost double those seen within 1 
year. BVSs increased risks for MI (OR, 1.63), target lesion 
revascularization (OR, 1.31), and target lesion failure (OR, 
1.37). Incidences of all-cause, cardiac, and noncardiac 
death and of target vessel and any revascularization did not 
differ (Zhang X-L et al, Ann Intern Med 2017;167:642-54).   
Patients with non-STEMI (NSTEMI) Who 
Demonstrate a Totally Occluded Culprit Vessel on 
Coronary Angiography are at Higher Risk of Mortality 
and Major Adverse Cardiac Events  
According to 7 studies with 40,777 NSTEMI patients, 
10,415 (25.5%) had an occluded culprit artery with a 
predominant infero-lateral distribution (40% right 
22 
 
 
coronary and 33% left circumflex artery). There was an 
increased risk of both MACE (short-term RR: 1.41; 
P = 0.0003; medium- to long-term RR: 1.32; P = 0.001) 
and all-cause mortality (short-term RR: 1.67; P < 0.0001; 
medium to long-term RR: 1.42; P = 0.01) with total 
occlusion of the culprit artery (Khan AR et al, Eur Heart J 
2017; 38:3082-89).   
Greater Reductions in Left Ventricular (LV) Mass 
With Sacubitril/ Valsartan Compared to Olmesartan  
Among 114 hypertensive patients receiving sacubitril/ 
valsartan (n=57) or olmesartan (n=57) (mean age 
59.8 years; 67.5% male), LV mass index decreased to a 
greater extent in the sacubitril/valsartan group compared to 
the olmesartan group from baseline to 12 weeks (−6.36 
vs. −2.32 g/m2; P = 0.039) and from baseline to 52 weeks 
(−6.83 vs. −3.55 g/m2; P = 0.029). These differences 
remained significant after adjustment for systolic blood 
pressure (SBP) at follow-up. There were no significant 
differences in local distensibility changes from baseline to 
12 or 52 weeks between the two groups; however, there 
was a larger reduction in central pulse pressure for the 
sacubitril/valsartan group (P = 0.010) (Schmieder RE et al, 
Eur Heart J 2017; 38: 3308–3317).   
PREVAIL & PROTECT AF Trials: 5-Year Outcomes 
After Left Atrial Appendage Closure (LAAC) in AF 
Patients Using the Watchman Device / Protection 
Against Ischemic Stroke and Systemic Embolism was 
Similar to Warfarin, but LAAC was Associated With 
Reductions in Hemorrhagic, Disabling and Fatal 
Stroke, Favorably Influencing Survival  
For the PREVAIL trial, the first composite coprimary 
endpoint of stroke, systemic embolism (SE), or 
cardiovascular (CV)/unexplained death did not achieve 
noninferiority, whereas the second coprimary endpoint of 
post-procedure ischemic stroke/SE did achieve 
noninferiority; the warfarin arm maintained an unusually 
low ischemic stroke rate (0.73%). In the meta-analysis 
(1,114 patients), the composite endpoint was similar 
between groups (hazard ratio -HR: 0.82), as were all-
stroke/SE (HR: 0.96). The ischemic stroke/SE rate was 
numerically but not statistically higher with LAAC (HR: 
1.71; p=0.080). However, differences in hemorrhagic 
stroke, disabling/ fatal stroke, CV/unexplained death, all-
cause death, and post-procedure bleeding favored LAAC 
(HR: 0.20; p=0.0022; HR: 0.45; p=0.03; HR: 0.59; 
p=0.027; HR: 0.73; p=0.035; HR: 0.48; p=0.0003, 
respectively) (Reddy VY et al, J Am Coll Cardiol 2017; 
70:2964-75).   
Hydroquinidine (HQ) Prevents Life-Threatening 
Arrhythmic Events (LAE) in Patients With Short QT 
Syndrome (SQTS) 
Among 17 SQTS patients (82% male, age 29 ± 3 years, 
QTc before treatment 331±3 ms) receiving HQ therapy 
(584 ± 53 mg/day) (stopped in 2 cases due to 
gastrointestinal intolerance) for 6 ± 1 years, QTc was 
prolonged in all patients (by 60 ± 6 ms; p< 0.001). Patients 
on HQ experienced a reduction in both the rate of LAE 
from 40% to 0% (p=0.03) and the number of LAE per 
patient from 0.73 ± 0.3 to 0 (p=0.026). The annual rate of 
LAE in the 16 patients with a previous cardiac arrest 
dropped from 12% before HQ to 0 on therapy (p=0.028). 
(Mazzanti A et al, J Am Coll Cardiol 2017; 70:3010-5).   
In 5 Patients with Refractory VT, Treatment with 
Noninvasive Electrophysiology (EP)-Guided Cardiac 
Radioablation Markedly Reduced the Burden of VT  
Noninvasive mapping using multielectrode body-
surface ECG (256 electrodes) to create a cardiac image and 
standard cardiac imaging (SPECT or CMR) was used to 
identify myocardial scar and the arrhythmogenic region 
(“exit site” of earliest electrical activation) during 
ventricular tachycardia (VT). This was combined with 
noninvasive ablation via stereotactic body radiation 
therapy (SBRT) (commonly used to treat tumors), which 
delivers precise, high-dose radiation to targets in the body 
(here a volumetric target for radioablation that targeted the 
area of the first 10 ms of VT, i.e. the exit site, and the full 
myocardial thickness of the associated ventricular scar) 
with minimal damage to normal adjacent tissue, to treat 
(with a single fraction of 25 Gy) 5 patients with refractory 
VT, induced and terminated with noninvasive program-
med stimulation via an ICD. The mean ablation time was 
14 min. During the 3 months before treatment, the patients 
had a combined history of 6577 episodes of VT. During a 
6-week postablation “blanking period” (when arrhythmias 
may occur owing to postablation inflammation), there 
were 680 episodes of VT. After the 6-week blanking 
period, there were 4 episodes of VT over the next 46 
patient-months, for a reduction from baseline of 99.9%. A 
reduction in episodes of VT occurred in all 5 patients. The 
mean LVEF did not decrease with treatment. At 3 months, 
adjacent lung showed opacities consistent with mild 
inflammatory changes, which had resolved by 1 year 
(Cuculich PS et al, N Engl J Med 2017;377:2325-36).  
Systematic Review, Network Meta-Analysis, and Cost 
Effectiveness Analysis: Apixaban Ranks Higher Than 
Other Direct-Acting Oral Anticoagulants (DOACs) for 
Preventing Stroke in Atrial Fibrillation (AF) Patients 
Analysis of 13 of 23 randomized trials involving 
94 656 patients, comparing a DOAC with warfarin, 
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apixaban 5 mg bid (odds ratio – OR 0.79), dabigatran 150 
mg bid (OR 0.65), edoxaban 60 mg qd (OR 0.86), and 
rivaroxaban 20 mg qd (OR 0.88) reduced the risk of stroke 
or systemic embolism. The risk of stroke or systemic 
embolism was higher with edoxaban 60 mg qd (OR 1.33) 
and rivaroxaban 20 mg qd (OR 1.35) than with dabigatran 
150 mg bid. The risk of all-cause mortality was lower with 
all DOACs than with warfarin. Apixaban 5 mg bid (OR 
0.71), dabigatran 110 mg bid (OR 0.80), edoxaban 30 mg 
qd (OR 0.46), and edoxaban 60 mg qd (OR 0.78) reduced 
the risk of major bleeding compared with warfarin. The 
risk of major bleeding was higher with 150 mg-dabigatran 
than apixaban (OR 1.33), rivaroxaban than apixaban 
(1.45), and rivaroxaban than 60 mg-edoxaban (OR 1.31). 
The risk of intracranial bleeding was substantially lower 
for most DOACs compared with warfarin, whereas the risk 
of gastrointestinal bleeding was higher with some DOACs 
than warfarin. Apixaban was ranked the highest for most 
outcomes, and was cost effective compared with warfarin 
(López-López JA et al, BMJ 2017;359:j5058 ).  
Transseptal Puncture (TSP) for Access to the Left 
Atrium: Employing a Standardized Protocol with Use 
of Fluoroscopy Alone Minimized Serious 
Complications to 0.8% (2 Patients) Among 249 
Consecutive Patients Undergoing TSP for Ablation of 
a Variety of Cardiac Arrhythmias   
Among 249 patients (aged 41.6±17.4 years, 146 men, 
33 children or young adolescents aged 7-18 years; 14 
patients undergoing a repeat procedure) undergoing TSP 
by a single operator for ablation of a variety of 
arrhythmias, mostly related to left accessory pathways 
(n=145), left atrial tachycardias (n=33) or atrial fibrillation 
(AF) (n=70), TSP was guided by fluoroscopy alone in all 
patients without the use of echocardiography imaging. 
Patients with a manifest accessory pathway were the 
youngest (mean age 33.7±15.9) and patients with AF the 
oldest (mean age 56.0±10.8 years). A successful TSP was 
accomplished in 247 patients (99.2%). Two (0.8%) 
procedures were complicated by cardiac tamponade 
managed successfully with pericardiocentesis or surgical 
drainage. Review of the literature revealed no systematic 
reviews and meta-analyses of TSP studies; however, 
several patient series have documented that fluoroscopy-
guided TSP, with various modifications in the technique 
employed in the present series, have been effective in 95-
100% of the cases with a complication rate ranging from 
0.0% to 6.7%, albeit with a mortality rate of 0.018%- 0.2%. 
Echo imaging techniques were employed in cases with 
difficult TSP. Based on this single-operator experience and 
review of the literature, a list of practical tips and tricks is 
provided for a successful and safe procedure, reserving the 
more expensive and patient inconveniencing echo-imaging 
techniques for difficult or failed cases (Manolis AS, Curr 
Cardiol Rev 2017;13: 305-318).  
 
CULPRIT-SHOCK Trial: 30-Day Risk of Death or 
Severe Renal Failure was Lower Among MI Patients in 
Cardiogenic Shock Who Initially Underwent PCI of the 
Culprit Lesion Only Than Among Those Who 
Underwent Immediate Multivessel PCI  
Among 706 patients who had multivessel disease, 
acute myocardial infarction (MI), and cardiogenic shock 
randomized to either PCI of the culprit lesion only, with 
the option of staged revascularization of nonculprit lesions, 
or immediate multivessel PCI, at 30 days, the composite 
primary end point of death or renal-replacement therapy 
had occurred in 158 of the 344 patients (45.9%) in the 
culprit-lesion-only PCI group and in 189 of the 341 
patients (55.4%) in the multivessel PCI group (relative 
risk, 0.83; P=0.01). The relative risk of death in the culprit-
lesion-only PCI group as compared with the multivessel 
PCI group was 0.84 (P=0.03), and the relative risk of renal-
replacement therapy was 0.71 (P=0.07) (Thiele H et al, N 
Engl J Med 2017; 377:2419-32).  
 
Legacy (Non-MRI Conditional) Devices Appear Safe 
During MRI / With Use of a Safety Protocol in 1509 
Patients Undergoing MRI, no Long-Term Clinically 
Significant Adverse Events Were Reported  
Among 1509 patients who had a pacemaker (58%) or 
an ICD (42%) that was not considered to be MRI-
conditional (termed a “legacy” device) undergoing 2103 
thoracic and nonthoracic MRI (1.5 Tesla) examinations 
with the pacing mode changed to asynchronous mode for 
pacing-dependent patients and to demand mode for other 
patients and the tachyarrhythmia functions disabled, no 
long-term clinically significant adverse events were 
reported. In 9 MRI examinations (0.4%), the patient’s 
device reset (transiently in 8) to a backup mode. In 1 case, 
a pacemaker with <1 month left of battery life reset to 
ventricular inhibited pacing (non-reprogrammable/ was 
replaced). The most common notable change in device 
parameters (>50% change from baseline) immediately 
after MRI was a decrease in P-wave amplitude, which 
occurred in 1% of the patients. At long-term follow-up 
(results of which were available for 63% of the patients), 
the most common notable changes from baseline were 
decreases in P-wave amplitude (4%), and increases in 
atrial (4%), right ventricular (4%), and left ventricular 
capture thresholds (3%). The observed changes in lead 
parameters were not clinically significant and did not 
require device revision or reprogramming (Nazarian S et 
al, N Engl J Med 2017; 377:2555-64).  
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In High-Risk Patients With Renal Artery Stenosis 
(RAS) and Resistant Hypertension, Flash Pulmonary 
Edema, and/or Rapid Deterioration of Renal Function, 
Renal Artery Stenting (PRS), a Procedure With High 
Technical Success, May Constitute a Viable Option 
In a series of 9 high-risk RAS patients with resistant 
hypertension (5 men, mean age 71 years), PRS was 
successful in all patients without complications and helped 
in bringing under control their elevated blood pressure 
(BP) and in maintaining their renal function over a mean 
of 21 months. Literature review of this controversial topic 
indicates that in carefully selected patients, PRS may play 
an important role in controlling BP, alleviating symptoms 
and perhaps preventing renal failure, albeit without 
concrete evidence of significantly affecting hard end-
points of renal events, major cardiovascular events and 
death. Randomized controlled studies (RCTs), including 
the large CORAL trial, although heavily criticized, have 
not provided evidence in favor of revascularization. 
Although RCTs are rather neutral, many prospective, 
observational cohort studies, comparing the outcomes of 
patients after PRS have demonstrated significant 
improvement in systolic and diastolic BP in about two 
thirds and improvement and/or stabilization in renal 
function in 30-40% of patients undergoing PRS. 
Nevertheless, the issue remains unsolved and a subject of 
future studies for further more definitive settlement. There 
are suggestions to adopt physiological and functional renal 
lesion assessment that may enhance patient selection, at 
least for RAS cases of moderate lesion severity (Manolis 
AS et al, Curr Hypertens Rev 2017; 13: 93-103).   
Meta-analysis: The Most Commonly Found New-Onset 
Arrhythmia Following TAVI is Atrial Fibrillation (AF) 
Among 65 studies (43 506 patients) reporting new-
onset arrhythmias following TAVI, new-onset AF (2641 
patients), bradyarrhythmias (182 patients; 4% prevalence 
at 1-year follow-up), supraventricular arrhythmias (29 
patients), ventricular arrhythmias (28 patients) and non-
specified major arrhythmias (855 patients) were reported. 
In most studies (52 out of 65), new-onset arrhythmia 
detection was limited to the first month following TAVI. 
The most frequently documented arrhythmia was AF with 
trend of increasing summary prevalence of 11%, 14%, 
14% and 25% during inhospital, 30-day, 1-year and 2-year 
follow-ups, respectively (P for trend=0.011). Summary 
prevalence estimates of new-onset AF at 30-day follow-up 
differ significantly between studies of prospective and 
retrospective design (8% and 21%, respectively, P=0.002). 
New onset AF increased risk of death (relative risk 1.61) 
& cerebrovascular events (1.79) (Siontis GCM et al, Heart 
2017 doi: 10.1136/heartjnl-2017-312310. Epub ahead of print) 
 
Important Review and Other Articles   
● 2017 AHA/ACC/HRS Guideline for Management of Patients 
With Ventricular Arrhythmias and the Prevention of Sudden 
Cardiac Death (Al-Khatib SM et al, J Am Coll Cardiol 2017 Oct 
25. pii: S0735-1097(17) 41306-4), 
● 2017 ACC/AHA/ Hypertension Guidelines (Whelton PK et al, 
J Am Coll Cardiol 2017, 24429; doi: 10.1016/j.jacc.2017.11.005)  
● Obesity and atrial fibrillation (Lavie CJ et al, J Am Coll 
Cardiol 2017;70:2022-35),  
● Interleukin-1 beta as a target for atherosclerosis therapy (Libby 
P, J Am Coll Cardiol 2017;70:2278-89),  
● PCSK-9 inhibitors (Hlatky MA et al, J Am Coll Cardiol 
2017;70: 2677-87), 
● Sudden death risk stratification in dilated cardiomyopathy 
(Manolis AS, Expert Rev Cardiovasc Ther 2017;15:315-325),  
● ACC Expert Consensus on management of mitral regurgitation 
(O’Gara PT et al, J Am Coll Cardiol 2017;70:2421-49),  
● Cardiovascular complications of cancer therapy (Chang H-M 
et al, J Am Coll Cardiol 2017;70:2536-65),        
● Appropriate use criteria for treatment of aortic stenosis 
(Bonow RO et al, J Am Coll Cardiol 2017;70:2566-98),             
● VT ablation (Dukkipati SR et al, J Am Coll Cardiol 2017;70: 
2909-41),  
● Wine and cardiovascular health (Haseeb S et al, Circulation 
2017;136:1434-48),  
● Sleep apnea and cardiovascular disease (Drager LF et al, 
Circulation 2017;136: 1840-50),  
● Risk stratification in arrhythmogenic right ventricular cardio-
myopathy (Calkins H et al, Circulation 2017;136:2068-82),  
● Handheld echocardiography (Chamsi-Pasha MA et al, 
Circulation 2017;136:2178-88),  
● Diuretic treatment in heart failure (Ellison DH & Felker GM, 
N Engl J Med 2017; 377:1964-1975),  
● Thrombo-embolic prevention after TAVI (Vranckx P et al, Eur 
Heart J 2017;38: 3341–3350),  
● 2017 ACC Expert Consensus Decision Pathway on 
Management of Bleeding in Patients on Oral Anticoagulants 
(Tomaselli GF et al, J Am Coll Cardiol 2017;70:3042-67),  
● TAVI for severe AS in patients with heart failure & low ejection 
fraction (Steiner J et al, J Am Coll Cardiol 2017;70: 3026-41),  
● Cardiac resynchronization therapy (Rao P & Faddis M, Heart 
2017;103:2000–7),  
● Transseptal puncture (Vahanian A & Brochet E, Heart 
2017;103: 830–1837),  
● Transseptal access to the left atrium: tips and tricks (Manolis 
AS, Curr Cardiol Rev 2017;13:305-318),  
● TAVI in nonagenarians (Manolis AS & Manolis AA, Ann 
Cardiothorac Surg 2017;6:524-531),  
● TAVI economics (Manolis AS, Ann Cardiothorac Surg 
2017;6:516-23),  
● Hypertension and cardiac arrhythmias (Lip G et al, Europace 
2017;19:891-911 & Eur Heart J Cardiovasc Pharmacother 
2017;3:235-250),  
● Atrial flutter (Manolis AS, Cardiol Rev 2017;25:289-297),  
● Structure & function of left atrium and left atrial appendage 
(Delgado V et al, J Am Coll Cardiol 2017;70:3157-72) 
